Daiwa Securities Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $683K | Buy |
20,468
+12,808
| +167% | +$318K | ﹤0.01% | 917 |
|
|
2026
Q1 | $160K | Buy |
7,660
+381
| +5% | +$8.58K | ﹤0.01% | 1035 |
|
|
2025
Q4 | $168K | Buy |
7,279
+371
| +5% | +$12.2K | ﹤0.01% | 1009 |
|
|
2025
Q3 | $208K | Buy |
6,908
+6,568
| +1,932% | +$197K | ﹤0.01% | 980 |
|
|
2025
Q2 | $12K | Buy |
340
+35
| +11% | +$1.26K | ﹤0.01% | 1115 |
|
|
2025
Q1 | $11K | Hold |
305
| – | – | ﹤0.01% | 1090 |
|
|
2024
Q4 | $13K | Sell |
305
-45
| -13% | -$2.23K | ﹤0.01% | 1105 |
|
|
2024
Q3 | $19K | Buy |
350
+46
| +15% | +$2.34K | ﹤0.01% | 1101 |
|
|
2024
Q2 | $12K | Hold |
304
| – | – | ﹤0.01% | 1156 |
|
|
2024
Q1 | $14K | Sell |
304
-32
| -10% | -$1.51K | ﹤0.01% | 1151 |
|
|
2023
Q4 | $16K | Buy |
336
+54
| +19% | +$2.09K | ﹤0.01% | 1144 |
|
|
2023
Q3 | $10K | Hold |
282
| – | – | ﹤0.01% | 1127 |
|
|
2023
Q2 | $13K | Hold |
282
| – | – | ﹤0.01% | 1128 |
|
|
2023
Q1 | $11K | Hold |
282
| – | – | ﹤0.01% | 1107 |
|
|
2022
Q4 | $13K | Buy |
282
+21
| +8% | +$826 | ﹤0.01% | 1102 |
|
|
2022
Q3 | $11K | Hold |
261
| – | – | ﹤0.01% | 1122 |
|
|
2022
Q2 | $16K | Buy |
261
+62
| +31% | +$3.81K | ﹤0.01% | 1122 |
|
|
2022
Q1 | $14K | Hold |
199
| – | – | ﹤0.01% | 1126 |
|
|
2021
Q4 | $17K | Sell |
199
-33
| -14% | -$2.69K | ﹤0.01% | 1125 |
|
|
2021
Q3 | $21K | Buy |
232
+99
| +74% | +$8.95K | ﹤0.01% | 1101 |
|
|
2021
Q2 | $13K | Hold |
133
| – | – | ﹤0.01% | 1035 |
|
|
2021
Q1 | $15K | Buy |
133
+9
| +7% | +$1.23K | ﹤0.01% | 1024 |
|
|
2020
Q4 | $17K | Sell |
124
-216
| -64% | -$25.6K | ﹤0.01% | 989 |
|
|
2020
Q3 | $28K | Buy |
340
+14
| +4% | +$1.16K | ﹤0.01% | 968 |
|
|
2020
Q2 | $14K | Hold |
326
| – | – | ﹤0.01% | 1048 |
|
|
2020
Q1 | $14K | Hold |
326
| – | – | ﹤0.01% | 1036 |
|
|
2019
Q4 | $14K | Sell |
326
-32
| -9% | -$1.32K | ﹤0.01% | 1037 |
|
|
2019
Q3 | $15K | Hold |
358
| – | – | ﹤0.01% | 1009 |
|
|
2019
Q2 | $23K | Hold |
358
| – | – | ﹤0.01% | 1002 |
|
|
2019
Q1 | $25K | Buy |
358
+98
| +38% | +$5.6K | ﹤0.01% | 982 |
|
|
2018
Q4 | $11K | Hold |
260
| – | – | ﹤0.01% | 993 |
|
|
2018
Q3 | $20K | Hold |
260
| – | – | ﹤0.01% | 1003 |
|
|
2018
Q2 | $20K | Hold |
260
| – | – | ﹤0.01% | 1010 |
|
|
2018
Q1 | $13K | Buy |
+260
| New | +$13.1K | ﹤0.01% | 1013 |
|
Other funds holding RARE
RI
FCM
Daiwa Securities Group's RARE Position: Q2 2026 in Review
Daiwa Securities Group increased its Ultragenyx Pharmaceutical (RARE) stake by 167% in Q2 2026, buying an estimated $318K and bringing the position to 20,468 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #917.
Daiwa Securities Group first reported a position in RARE in Q1 2018 and has held it in 34 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Daiwa Securities Group held 20,468 shares of Ultragenyx Pharmaceutical worth $683K as of Q2 2026.
- Daiwa Securities Group bought 12,808 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $318K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #917 holding.
- Daiwa Securities Group first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 34 quarters since.
- 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.